Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

10.5 Soft tissue and joint disorders

Checked: not set yet by Next Review: not set yet

10.5.1 Local inflammation of joints and soft tissue

First line drugs Second line drugs Specialist drugs Secondary care drugs


Link to BNF Corticosteroids, inflammatory disorders


  • Treatment with corticosteroids in rheumatic diseases should be reserved for specific indications e.g. when other anti-inflammatory drugs are unsuccessful. 
  • Corticosteroids may reduce bone density and increase the risk of low impact fracture and can induce osteoporosis. Patients taking (or who are likely to take) an oral corticosteroid at an equivalent dose of 5mg prednisolone or more, for 3 months or longer should be assessed using the FRAX® algorithm and where necessary offered appropriate given prophylactic treatment. See BNF section 6.6  

Prednisolone (TLS Green)


Methylprednisolone (TLS Blue)


Local Corticosteroid Injections

Hydrocortisone acetate (Hydrocortistab®) (TLS Green)

Triamcinolone acetonide (Kenalog®) (TLS Green)

Methylprednisolone acetate (Depo-Medrone®) (TLS Green)

Methylprednisolone acetate / Lidocaine (Depo-Medrone® with Lidocaine) (TLS Green)


10.5.2 Soft tissue disorders

Link to BNF Soft-tissue disorders



Hyaluronidase (TLS Blue)

  • Not the intra-articular preparation e.g. Synvisc®

Collagenase (TLS Red)

  • NICE TA459 collagenase clostridium histolyticum for treating Dupuytren's contracture



Dibotermin alfa (TLS Red)


Contact Us

Got a question or comment about the Joint Formulary? 

Please use the email address below to contact us and we will endeavour to respond within 2 working days.